MolecularMD

The companies will work together to create an end-to-end workflow for biomarker and drug target validation, and assay development.

Researchers are using Bio-Rad's droplet digital PCR technology to validate seven ctDNA biomarkers that may predict melanoma recurrence.

The two companies have established a broad framework that will enable them to collaborate on specific projects to develop NGS-based companion diagnostics.

The companies will combine MolecularMD's specialty diagnostic assays with Definiens' quantitative tissue read-outs to provide customized diagnostic solutions in oncology.

MolecularMD's assay will be used to select patients for a Phase II clinical trial in Europe to test an unspecified oncology therapy from Daiichi Sankyo.

The firm's NGS-based Notch 1 mutation detection test will be used to enroll patients in clinical trials.

The NGS laboratory has validated methods and platforms for circulating tumor DNA analysis.

NEW YORK (GenomeWeb News) – Molecular diagnostics company MolecularMD has received CLIA certification for its next-generation sequencing laboratory in Cambridge, Mass.

This article has been updated with additional details about the ClonoSIGHT test and to clarify that Sequenta is in discussions with the FDA to transition the diagnostic from a lab test to a kit.

NEW YORK (GenomeWeb News) – MolecularMD said today it is working with drug firm Novartis to develop a companion diagnostic that can help determine which Philadelphia chromosome-positive chronic myeloid leukemia patients have achieved durable minimal residual disease after treatment with Tasigna (

Pages

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.